🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

BMI and obesity were not predictors of confirmed #PE among patients presenting with a clinical suspicion of PE. The age-adjusted D-dimer strategy appeared safe in ruling out PE in obese patients. Thrombosis & Haemostasis, TH,TH Open Aurélien Delluc Greta Legallo Tobias Tritschler #VTE thieme-connect.com/products/ejour…

Obesity is a risk factor for PE but is the standard workup appropriate? Tobias Tritschler shares findings of a posthoc analysis of the ADJUST PE study INVENT-VTE CanVECTOR Network #ISTH2023 @grelegal

Dr Tobias Tritschler demonstrated that BMI does not affect the efficacy of age adjusted D-diner in patients with suspected PE at #ISTH2023 Very reassuring!! Check for full manuscript in Thrombosis & Haemostasis, TH,TH Open CanVECTOR Network INVENT-VTE

Are you a VTE researcher interested in collaboration? Please complete our 5 minute survey for feedback on the initiative TrialHive: survey.ucalgary.ca/jfe/form/SV_bJ… INVENT-VTE CanVECTOR Network Marc Rodger Greta Legallo Tobias Tritschler Lisa Duffett Deborah Siegal Leslie Skeith #ISTH2023

.Yan Xu nicely describes why it’s critical to assess for the competing risk of death when assessing survival from a disease/recurrence. Kaplan-Meier analysis may over-estimate incidence. #ISTH2023

Patients with unprovoked VTE have substantial risks of overall mortality following anticoagulant discontinuation (< 20% fatal PE). In patients > 75 years, risk of overall mortality should be considered in decision-making about duration of anticoagulation. #ISTH2023 Yan Xu

📣Coinciding with #ISTH2023, the final Chapter of my #PhD is published today in Annals of Int Med! THREAD below detailing our study in which we quantified the benefit-harm tradeoffs of indefinite anticoagulation (AC) for unprovoked #VTE…🧵 acpjournals.org/doi/10.7326/M2…

Late breaking at #ISTH2023 by Greta Legallo SYMPTOMS trial (n=2559) randomized patients hospitalized medically ill elderly patients to enoxaparin 40 mg daily or placebo. Trial stopped early but no difference in symptomatic VTE at 30 days! #ISTH2023 evidence.nejm.org/doi/full/10.10…

Extended (indefinite) #cvCoag care is guideline-recommended for patients with unprovoked #VTE. But is this cost effective or associated with improved QOL? Dr Piazza highlights a modeling paper suggesting that we may need to reconsider our approach. #SVM23

🆕 Superb editorial in #EuropeanHeartJournal by Marc Carrier and Peter Verhamme on the most challenging & much debated question for physicians involved in the care of patients with #VTE: how long to treat? Open Access: academic.oup.com/eurheartj/adva…

So proud of my ⭐️ team of coauthors Tobias Tritschler Professor Susan R Kahn and Marc Rodger for our Seminar on #VTE reaching its 300th citation in just 2.5 years since its publication in The Lancet 🎉 thelancet.com/article/S0140-…

Sad to have missed #ICTHIC2024 this year. Thanks Marc Carrier for presenting our meta-analysis of prognostic factors associated w/ recurrent #VTE in patients with cancer-associated VTE. Stay tuned for the full publication, including factors for bleeding in these patients.

Looking forward to the results of this important project on racial disparities in postpartum VTE by Yan Xu, presented at #ISTH2024 by ISTH Outstanding Mentor Award recipient Marc Carrier.

Dr. Nicola Potere reported that 15.5% of patients with distal DVT had recurrence following anticoagulation discontinuation. Patients with unprovoked events or diabetes and those only receiving 6 weeks of anticoagulation, are at higher risk of recurrent events! #ISTH2024

Interested in developing a clinical prediction model? Check out our new paper 🥳🥳🥳 in the The BMJ where we present a step-by-step guide bmj.com/content/386/bm… Together with Matthias Egger @Geointheworld Konstantina Chalkou Thomas Debray. Special thanks to Richard Riley (R²) for his help!

We’re thrilled to announce Carol West as our Patient Ambassador of the Year! 🎉This award celebrates Carol’s incredible dedication to raising awareness about thrombosis in her community 🙌 A special shoutout to Arielle Dance for receiving an honorable mention.

In non-critically ill patients with COVID-19, therapeutic-dose anticoagulation reduced organ support, thrombosis, and death by 28 days, but increased bleeding risk (though absolute risk stayed low). No high-credibility effect modifiers found. Great work Tobias Tritschler! #ISTH2025

Is this the end of rivaroxaban for acute VTE? Lana Castellucci presenting the COBBRA trial - 1st RCT comparing apixaban to riva over 3 months. 56% reduction in bleeding risk with apixaban. A safer Rx with the same efficacy. #ISTH2025

🩸 Meta-analysis presented at #ISTH2025 and simultaneously published in EHJ Editor-in-Chief found that several risk factors (e.g., previous history of VTE or bleeding, advanced cancer, and specific cancer sites) are associated with recurrent VTE and bleeding in patients with CAT.

🚨📣 A long-awaited study from my #BantingCanada fellowship examining predictors of recurrent #VTE and anticoagulant-related🩸 #bleeding in patients with cancer was published in #EHJ today to coincide with my live presentation at #ISTH2025‼️ academic.oup.com/eurheartj/adva…